Peter Olejnik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Peter Olejnik has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Marko Bjeloševič
Department of Paediatric Cardiology, Faculty of Medicine Comenius University in Bratislava Bratislava Slovakia
3 shared publications Beatrice Bonnello
Department of Paediatric Cardiology, Great Ormond Street Hospital , London
2 shared publicationsDiala Khraiche
Department of Pediatric, Necker Hospital, Paris , France
2 shared publications- Giovanni Di Salvo
Department of Woman and Child Health, Paediatric Cardiology and Congenital Heart Disease, University of Padova , Padova
2 shared publications - Inga Voges
Department for Congenital Cardiology and Pediatric Cardiology, University Hospital Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany
2 shared publications - Jaroslav Tomko
Department of Arrhythmias and Cardiac Pacing Paediatric Cardiac Centre, National Institute of Cardiovascular Diseases in Bratislava Bratislava Slovakia
2 shared publications
Latest Publications
- Open Access
- 2 July 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Imaging Methods and Practice
- Vol. 4 (3) , qyag132
Applications of speckle tracking echocardiography in paediatric and congenital heart disease: an expert consensus paper from AEPC Imaging Working Group
This document has been developed to provide a practical guide for the application of speckle tracking echocardiography (STE) in paediatric and congenital heart diseases. In the present document, the following topics are reviewed and discussed: (i) the basic principles of STE, its potential applications, and limitations in the paediatric population; (ii) normal paediatric reference values for STE; and (iii) the use of STE in various congenital and acquired heart diseases. The potential role of routine STE in the management and follow-up of paediatric and congenital heart disease is explored, with practical examples illustrating how STE can provide additional insights beyond conventional echocardiographic parameters. Limitations regarding clinical interpretation, prognostic value, the lack of standardized timing for measurements, and the absence of universally accepted thresholds for STE-derived strain parameters are also highlighted. Overall, this document is intended to serve as a comprehensive guide to (i) orient clinicians regarding the strengths and limitations of STE in paediatric and congenital heart disease; (ii) identify specific clinical scenarios where STE may be particularly informative; and (iii) encourage future research and multicentre collaborative studies. By providing both practical guidance and a framework for further investigation, the document aims to support standardized use of STE, improve patient care, and foster the integration of this technique into routine paediatric and congenital cardiology practice.
- 2 July 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Imaging Methods and Practice
- Vol. 4 (3) , qyag132
Open AccessApplications of speckle tracking echocardiography in paediatric and congenital heart disease: an expert consensus paper from AEPC Imaging Working Group
This document has been developed to provide a practical guide for the application of speckle tracking echocardiography (STE) in paediatric and congenital heart diseases. In the present document, the following topics are reviewed and discussed: (i) the basic principles of STE, its potential applications, and limitations in the paediatric population; (ii) normal paediatric reference values for STE; and (iii) the use of STE in various congenital and acquired heart diseases. The potential role of routine STE in the management and follow-up of paediatric and congenital heart disease is explored, with practical examples illustrating how STE can provide additional insights beyond conventional echocardiographic parameters. Limitations regarding clinical interpretation, prognostic value, the lack of standardized timing for measurements, and the absence of universally accepted thresholds for STE-derived strain parameters are also highlighted. Overall, this document is intended to serve as a comprehensive guide to (i) orient clinicians regarding the strengths and limitations of STE in paediatric and congenital heart disease; (ii) identify specific clinical scenarios where STE may be particularly informative; and (iii) encourage future research and multicentre collaborative studies. By providing both practical guidance and a framework for further investigation, the document aims to support standardized use of STE, improve patient care, and foster the integration of this technique into routine paediatric and congenital cardiology practice.
- Open Access
- 8 March 2026
- Published by Wiley in Journal of Arrhythmia
- Vol. 42 (2)
Implantable Cardioverter‐Defibrillators in Children: A 14‐Year Population‐Based Study
Aims: Implantable cardioverter‐defibrillator (ICD) therapy in children, particularly for primary prevention, remains under investigation, with limited data from less affluent European countries. With increasing use of fully subcutaneous (S‐ICD) and extravascular (EV‐ICD) systems, we analyzed epidemiology, indications, complications, and outcomes in pediatric ICD recipients at our tertiary center. Methods: This retrospective, population‐based, nationwide, single‐center study consecutively analyzed medical records from 2012 to 2025. Patients aged 0–18 years who underwent ICD implantation were included. Kaplan–Meier analyses were performed for shock‐free and mortality endpoints. Results: Forty‐nine patients were included, corresponding to an estimated national incidence of approximately one ICD implantation per 22 000 live births. ICDs were predominantly implanted for secondary prevention (80%). Long QT syndrome (32%) and hypertrophic cardiomyopathy (22%) were the most frequent diagnoses. During 207 patient‐years of follow‐up (median follow‐up 4 years), appropriate ICD shocks occurred in 27% of patients exclusively in the secondary prevention group. No appropriate therapies occurred in the primary prevention group despite higher overall mortality. Inappropriate shocks occurred in 22% of patients. Device‐related major complications affected 17% of implanted systems. Median transvenous ICD battery longevity was 6.5 years. Overall mortality was 6%, all related to underlying structural heart disease, with no ICD‐related deaths. S‐ICDs demonstrated a favorable acute and mid‐term safety profile in patients without pacing requirements. Conclusions: Pediatric ICD therapy is limited by substantial device‐related morbidity and imperfect risk stratification for primary prevention. The emerging S‐ICD and EV‐ICD systems represent promising, less invasive alternatives for selected pediatric patients.
- 8 March 2026
- Published by Wiley in Journal of Arrhythmia
- Vol. 42 (2)
Open AccessImplantable Cardioverter‐Defibrillators in Children: A 14‐Year Population‐Based Study
Aims: Implantable cardioverter‐defibrillator (ICD) therapy in children, particularly for primary prevention, remains under investigation, with limited data from less affluent European countries. With increasing use of fully subcutaneous (S‐ICD) and extravascular (EV‐ICD) systems, we analyzed epidemiology, indications, complications, and outcomes in pediatric ICD recipients at our tertiary center. Methods: This retrospective, population‐based, nationwide, single‐center study consecutively analyzed medical records from 2012 to 2025. Patients aged 0–18 years who underwent ICD implantation were included. Kaplan–Meier analyses were performed for shock‐free and mortality endpoints. Results: Forty‐nine patients were included, corresponding to an estimated national incidence of approximately one ICD implantation per 22 000 live births. ICDs were predominantly implanted for secondary prevention (80%). Long QT syndrome (32%) and hypertrophic cardiomyopathy (22%) were the most frequent diagnoses. During 207 patient‐years of follow‐up (median follow‐up 4 years), appropriate ICD shocks occurred in 27% of patients exclusively in the secondary prevention group. No appropriate therapies occurred in the primary prevention group despite higher overall mortality. Inappropriate shocks occurred in 22% of patients. Device‐related major complications affected 17% of implanted systems. Median transvenous ICD battery longevity was 6.5 years. Overall mortality was 6%, all related to underlying structural heart disease, with no ICD‐related deaths. S‐ICDs demonstrated a favorable acute and mid‐term safety profile in patients without pacing requirements. Conclusions: Pediatric ICD therapy is limited by substantial device‐related morbidity and imperfect risk stratification for primary prevention. The emerging S‐ICD and EV‐ICD systems represent promising, less invasive alternatives for selected pediatric patients.
- 30 December 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 27 (5) , 941-951
Organization of paediatric and congenital echocardiography laboratories and governance of echocardiography services and training in Europe. A Statement of the EACVI of the ESC, the AEPC, and the ESC Working Group on Adult Congenital Heart Disease
This document has been developed as a comprehensive roadmap to the organization of paediatric and congenital echocardiography laboratories, as well as the governance of echocardiography services and training across Europe. The following key topics will be reviewed and discussed: (i) the setup and organization of paediatric and congenital echocardiography laboratories; (ii) staffing requirements for these laboratories; (iii) work time organization; and (iv) quality improvement processes. This document aims to identify the minimum number of medical and allied health professional staff required for each laboratory based on specific workload demands, whilst also detailing the basic medical accreditation requirements needed. Principles of work time organization will be addressed, including the time allocation needed for various types of echocardiographic examinations (e.g. first-time or complex examinations, follow-up, and quick assessments). The necessary time and space for reporting, communicating results (e.g. discussions with parents, liaising with other departments), and overall workflow will also be analysed. Additionally, quality improvement processes will be discussed, with a focus on strategies and minimum requirements for enhancing training and teaching. Approaches to encourage and support research initiatives within paediatric and congenital echocardiography laboratories will also be outlined. This document is intended to serve as a comprehensive roadmap to: (a) defining the basic facilities necessary for paediatric and congenital echocardiography laboratories; (b) detailing basic certification/accreditation requirements. (c) Optimizing staffing based on workload volumes; (d) establishing the minimal time requirements for performing and reporting on different types of congenital echocardiographic examinations; and (e) implementing strategies to optimize training, quality improvement, and research.
- 30 December 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 27 (5) , 941-951
Organization of paediatric and congenital echocardiography laboratories and governance of echocardiography services and training in Europe. A Statement of the EACVI of the ESC, the AEPC, and the ESC Working Group on Adult Congenital Heart Disease
This document has been developed as a comprehensive roadmap to the organization of paediatric and congenital echocardiography laboratories, as well as the governance of echocardiography services and training across Europe. The following key topics will be reviewed and discussed: (i) the setup and organization of paediatric and congenital echocardiography laboratories; (ii) staffing requirements for these laboratories; (iii) work time organization; and (iv) quality improvement processes. This document aims to identify the minimum number of medical and allied health professional staff required for each laboratory based on specific workload demands, whilst also detailing the basic medical accreditation requirements needed. Principles of work time organization will be addressed, including the time allocation needed for various types of echocardiographic examinations (e.g. first-time or complex examinations, follow-up, and quick assessments). The necessary time and space for reporting, communicating results (e.g. discussions with parents, liaising with other departments), and overall workflow will also be analysed. Additionally, quality improvement processes will be discussed, with a focus on strategies and minimum requirements for enhancing training and teaching. Approaches to encourage and support research initiatives within paediatric and congenital echocardiography laboratories will also be outlined. This document is intended to serve as a comprehensive roadmap to: (a) defining the basic facilities necessary for paediatric and congenital echocardiography laboratories; (b) detailing basic certification/accreditation requirements. (c) Optimizing staffing based on workload volumes; (d) establishing the minimal time requirements for performing and reporting on different types of congenital echocardiographic examinations; and (e) implementing strategies to optimize training, quality improvement, and research.
- Open Access
- 11 November 2021
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 5 (12) , ytab455
Percutaneous treatment of a huge patent ductus venosus and severe portal vein hypoplasia using a Figulla Flex II atrial septal defect occluder in a 2-year-old infant: a case report
Background: Intra- or extrahepatic porto-caval shunts (PCSs) can account for multiorgan dysfunction with pulmonary arterial hypertension and portosystemic encephalopathy as the most serious consequences of bypass of the hepatic circulation. The ductus venosus (DV) represents a rare foetal PCS and might be persistently patent in newborns after birth. Treatment strategies include surgical ligation and percutaneous device closure. The degree of portal vein hypoplasia limits therapy making liver transplantation the only option in some of them. Case summary: In a newborn female patient a huge persistently patent DV, known already prenatally, resulted in severe secondary portal vein hypoplasia. She presented with hyperammonaemia, elevated liver enzymes, and pulmonary hypertension. With only diminutive portal venous branches and exceedingly high portal venous pressures during test-occlusion of the DV, shunt closure was not possible. At the age of 2 years more favourable portal venous pressures allowed transcatheter device closure with a nitinol atrial septal defect occlusion device. Pulmonary artery pressures and ammonia levels normalized after the procedure without any signs of portal hypertension. Discussion: The case highlights the importance of meticulous imaging using balloon occlusion angiography of PCSs like the DV, to search for intrahepatic portal veins. Moreover, portal vein pressure during test-occlusion can identify patients amenable for surgical or endovascular shunt closure. Occlusion devices licensed for other indications like atrial septal defect closure can be used safely in huge PCS vessels in a one-step or staged procedure. Optimal timing of the intervention should be tailored to the patient’s needs
- 11 November 2021
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 5 (12) , ytab455
Open AccessPercutaneous treatment of a huge patent ductus venosus and severe portal vein hypoplasia using a Figulla Flex II atrial septal defect occluder in a 2-year-old infant: a case report
Background: Intra- or extrahepatic porto-caval shunts (PCSs) can account for multiorgan dysfunction with pulmonary arterial hypertension and portosystemic encephalopathy as the most serious consequences of bypass of the hepatic circulation. The ductus venosus (DV) represents a rare foetal PCS and might be persistently patent in newborns after birth. Treatment strategies include surgical ligation and percutaneous device closure. The degree of portal vein hypoplasia limits therapy making liver transplantation the only option in some of them. Case summary: In a newborn female patient a huge persistently patent DV, known already prenatally, resulted in severe secondary portal vein hypoplasia. She presented with hyperammonaemia, elevated liver enzymes, and pulmonary hypertension. With only diminutive portal venous branches and exceedingly high portal venous pressures during test-occlusion of the DV, shunt closure was not possible. At the age of 2 years more favourable portal venous pressures allowed transcatheter device closure with a nitinol atrial septal defect occlusion device. Pulmonary artery pressures and ammonia levels normalized after the procedure without any signs of portal hypertension. Discussion: The case highlights the importance of meticulous imaging using balloon occlusion angiography of PCSs like the DV, to search for intrahepatic portal veins. Moreover, portal vein pressure during test-occlusion can identify patients amenable for surgical or endovascular shunt closure. Occlusion devices licensed for other indications like atrial septal defect closure can be used safely in huge PCS vessels in a one-step or staged procedure. Optimal timing of the intervention should be tailored to the patient’s needs
- 27 May 2020
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 43 (7) , 680-686
Supraventricular tachyarrhythmias during the intrauterine, neonatal, and infant period: A 10‐year population‐based study
Background We aimed to evaluate the incidence, type and management of supraventricular tachyarrhythmias (SVT) during the first year of life in a retrospective, population‐based, single‐center study during a 10‐year period. Methods The analyzed patient cohort is based on data from the only specialized center managing all cases of neonatal and infant SVTs between 2009 and 2018 in the Slovak Republic (5.5 million population). A total of 116 consecutive patients < 366 days old were included in the study. Results Calculated SVT incidence was 1:4500 in the first year of life. AV reentry tachycardia was the leading arrhythmia (49%). SVT in this specific population was frequently a transient problem with spontaneous resolution in 87% of patients during a median 3‐year follow‐up. Congenital heart disease was common (16%). Intrauterine treatment by drugs administered to mother was safe and effective in preventing unnecessary cesarean deliveries. In arrhythmia termination amiodarone and propafenone were equally safe and effective, with possible more favorable pharmacodynamics of the former. For prophylactic treatment sotalol and propafenone were equally safe and effective and became the preferred basis of long‐term drug therapy in our center. However, this therapy requires intensive monitoring during its initiation. Conclusion The prognosis of SVT in the first year of life is good: with optimized pharmacological treatment the need for early catheter ablation and mortality rate are low (< 1%) and there is a high rate of spontaneous arrhythmia resolution. Heart failure is a possible predictor of arrhythmia persistence with need for ablation in later life. This article is protected by copyright. All rights reserved
- 27 May 2020
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 43 (7) , 680-686
Supraventricular tachyarrhythmias during the intrauterine, neonatal, and infant period: A 10‐year population‐based study
Background We aimed to evaluate the incidence, type and management of supraventricular tachyarrhythmias (SVT) during the first year of life in a retrospective, population‐based, single‐center study during a 10‐year period. Methods The analyzed patient cohort is based on data from the only specialized center managing all cases of neonatal and infant SVTs between 2009 and 2018 in the Slovak Republic (5.5 million population). A total of 116 consecutive patients < 366 days old were included in the study. Results Calculated SVT incidence was 1:4500 in the first year of life. AV reentry tachycardia was the leading arrhythmia (49%). SVT in this specific population was frequently a transient problem with spontaneous resolution in 87% of patients during a median 3‐year follow‐up. Congenital heart disease was common (16%). Intrauterine treatment by drugs administered to mother was safe and effective in preventing unnecessary cesarean deliveries. In arrhythmia termination amiodarone and propafenone were equally safe and effective, with possible more favorable pharmacodynamics of the former. For prophylactic treatment sotalol and propafenone were equally safe and effective and became the preferred basis of long‐term drug therapy in our center. However, this therapy requires intensive monitoring during its initiation. Conclusion The prognosis of SVT in the first year of life is good: with optimized pharmacological treatment the need for early catheter ablation and mortality rate are low (< 1%) and there is a high rate of spontaneous arrhythmia resolution. Heart failure is a possible predictor of arrhythmia persistence with need for ablation in later life. This article is protected by copyright. All rights reserved
- Open Access
- 18 September 2018
- Published by AVES YAYINCILIK A.Ş. in Balkan Medical Journal
- Vol. 35 (6) , 451-452
Pediatric Mercury Intoxication Mimicking Pheochromocytoma
- 18 September 2018
- Published by AVES YAYINCILIK A.Ş. in Balkan Medical Journal
- Vol. 35 (6) , 451-452
Open AccessPediatric Mercury Intoxication Mimicking Pheochromocytoma